Brainstorm Cell Therapeutics (BCLI) Tops Q2 EPS by 2c
Tweet
Share
E-mailGet Alerts BCLI Hot Sheet
Join SI Premium – FREE
Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q2 EPS of ($0.12), $0.02 better than the analyst estimate of ($0.14).
For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ackman adds Netflix, Visa and Mastercard in portfolio revamp
- Bending Spoons S.p.A. (BSP) Tops Q2 EPS by 19c; offers guidance
- Live Ventures (LIVE) Reports Q3 Loss of $0.34
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
